About Jennerex Biotherapeutics
Jennerex Biotherapeutics is a company based in San Francisco (United States) founded in 2003 was acquired by SillaJen in November 2013.. Jennerex Biotherapeutics has raised $46.9 million across 6 funding rounds from investors including SillaJen and The Ottawa Cancer Foundation. The company has 7 employees as of December 31, 2021. Jennerex Biotherapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter San Francisco, United States
- Employees 7 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Sillajen Biotherapeutics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Jennerex Biotherapeutics
Jennerex Biotherapeutics has successfully raised a total of $46.9M across 6 strategic funding rounds. The most recent funding activity was a Series F round of $21.6 million completed in May 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series F — $21.6M
-
First Round
First Round
(18 Sep 2009)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2013 | Amount | Series F - Jennerex Biotherapeutics | Valuation |
investors |
|
| Jan, 2012 | Amount | Series E - Jennerex Biotherapeutics | Valuation |
investors |
|
| Oct, 2011 | Amount | Series E - Jennerex Biotherapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Jennerex Biotherapeutics
Jennerex Biotherapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include SillaJen and The Ottawa Cancer Foundation. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Community-based supportive care is provided for cancer patients in Ottawa.
|
Founded Year | Domain | Location | |
|
Oncolytic immunotherapeutics are developed for cancer treatment.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Jennerex Biotherapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Jennerex Biotherapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Jennerex Biotherapeutics Comparisons
Competitors of Jennerex Biotherapeutics
Jennerex Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Jennerex Biotherapeutics
Frequently Asked Questions about Jennerex Biotherapeutics
When was Jennerex Biotherapeutics founded?
Jennerex Biotherapeutics was founded in 2003 and raised its 1st funding round 6 years after it was founded.
Where is Jennerex Biotherapeutics located?
Jennerex Biotherapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Jennerex Biotherapeutics a funded company?
Jennerex Biotherapeutics is a funded company, having raised a total of $46.9M across 6 funding rounds to date. The company's 1st funding round was a Series E of $1.75M, raised on Sep 18, 2009.
How many employees does Jennerex Biotherapeutics have?
As of Dec 31, 2021, the latest employee count at Jennerex Biotherapeutics is 7.
What does Jennerex Biotherapeutics do?
Jennerex Biotherapeutics was founded in 2003 in San Francisco, United States, as a clinical-stage biopharmaceutical firm. Focus is placed on targeted oncolytic viruses to treat cancer. The lead product, JX-594, undergoes international Phase 2 trials for primary liver cancer and colorectal cancer. Additional candidates include JX-929 for pancreatic cancer and JX-1395 for prostate cancer. Acquisition by SillaJen occurred in 2014.
Who are the top competitors of Jennerex Biotherapeutics?
Jennerex Biotherapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Who are Jennerex Biotherapeutics's investors?
Jennerex Biotherapeutics has 2 investors. Key investors include SillaJen, and The Ottawa Cancer Foundation.